Apnimed Reports Positive Topline Results From Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea

A pill for sleep apnea could be on the horizon

Experts say that if the new drug gets approved, it may lead to a big shift in how we treat the condition.

Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea

LunAIRo, Apnimed's second Phase 3 trial of AD109, met its primary endpoint, demonstrating a reduction in the Apnea-Hypopnea Index (AHI) from baseline at 26...

Apnimed Reports Positive Topline Results from Second Phase 3 Trial of AD109, Reinforcing Potential of First Oral Pill for Obstructive Sleep Apnea - PressReach

Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that address the root causes of obstructive sleep apnea (OSA) and

Investigational AD109 Meets End Points in Phase 3 LunAIRo Trial, Eyeing FDA Submission for Obstructive Sleep Apnea

Apnimed's AD109 shows promising results in treating obstructive sleep apnea, potentially revolutionizing care for millions with a once-daily oral medication.

Positive Topline Results From Phase 3 Trial of AD109, First Oral Pill for Obstructive Sleep Apnea

Apnimed reveals promising results for AD109, a groundbreaking oral treatment for obstructive sleep apnea.

Apnimed announces results from second study of sleep apnea drug

On July 23, Apnimed announced positive topline results from LunAIRo, the second phase 3 clinical trial of AD109 (aroxybutynin 2.5mg, atomoxetine 75mg) in adults with obstructive sleep apnea. Apnimed previously announced results from its SynAIRgy trial of AD109 in May. LunAIRo study results Apnimed reports that the 12-month LunAIRo study demonstrated clinically meaningful and statistically significant reductions in airway obstruction at 26 weeks.…